

L5 ANSWER 1 OF 1 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD  
 AN 1992-400703 [49] WPIDS  
 DNC C1992-177709  
 TI New 4-(-(2-hydroxy-2-phenyl ethylamino) ethoxy) phenyl acetic acid - is  
 beta 3-adrenoceptor agonist, hyperlipidaemia, atherosclerosis,  
 inflammatory bowel disease etc..  
 DC B05  
 IN HOLLOWAY, B R; HOWE, R; RAO, B S; HOLLAWAY, B R; BALBIR, S R  
 PA (ZENE) ZENECA LTD; (ICIL) IMPERIAL CHEM IND PLC  
 CYC 32  
 PI EP----516349 A2 19921202 (199249)\* EN 20p  
 R: AT BE CH DE DK ES FR GB GR IT LI LU MC NL PT SE  
 AU---9217044 A 19921203 (199304)  
 NO---9202113 A 19921130 (199305)  
 BR---9202002 A 19930112 (199306)  
 CA---2068377 A 19921129 (199308)  
 FI---9202424 A 19921129 (199308)  
 CS---9201592 A2 19921216 (199317)  
 HU-----62256 T 19930428 (199322)  
 TW---198709 A 19930121 (199326)  
 ZA---9203356 A 19930526 (199327) 40p  
 JP--05148196 A 19930615 (199328) 16p <--  
 CN---1069023 A 19930217 (199351)  
 EP---516349 A3 19930414 (199351)  
 AU---652826 B 19940908 (199437)  
 NZ---242643 A 19941222 (199505)  
 US---5393779 A 19950228 (199514) 11p  
 US---5434184 A 19950718 (199534) 11p  
 EP---516349 B1 19950920 (199542) EN 34p  
 R: AT BE CH DE DK ES FR GB GR IT LI LU MC NL PT SE  
 DE--69204906 E 19951026 (199548)  
 ES---2076688 T3 19951101 (199550)  
 US---5480910 A 19960102 (199607) 10p

BEST AVAILABLE COPY

IE-----69043 B 19960807 (199645)  
RO-----111569 B1 19961129 (199725)  
HU-----211401 B 19951128 (199733)  
RU---2073666 C1 19970220 (199739) 17p  
ADT EP-----516349 A2 1992EP-0304653 19920522; AU---9217044 A 1992AU-0017044  
19920521; NO---9202113 A 1992NO-0002113 19920527; BR---9202002 A  
1992BR-0002002 19920527; CA---2068377 A 1992CA-2068377 19920511;  
FI---9202424 A 1992FI-0002424 19920527; CS---9201592 A2 1992CS-0001592  
19920526; HU-----62256 T 1992HU-0001609 19920515; TW----198709 A  
1992TW-0104319 19920602; ZA---9203356 A 1992ZA-0003356 19920508;  
JP--05148196 A 1992JP-0134846 19920527; CN---1069023 A 1992CN-0103977  
19920526; EP-----516349 A3 1992EP-0304653 19920522; AU-----652826 B  
1992AU-0017044 19920521; NZ---242643 A 1992NZ-0242643 19920507;  
US---5393779 A 1992US-0889196 19920528; US---5434184 A Div ex  
1992US-0889196 19920528, 1994US-0344708 19941118; EP-----516349 B1  
1992EP-0304653 19920522; DE--69204906 E 1992DE-0604906 19920522,  
1992EP-0304653 19920522; ES---2076688 T3 1992EP-0304653 19920522;  
US---5480910 A Div ex 1992US-0889196 19920528, Cont of 1994US-0344708  
19941118, 1995US-0437988 19950510; IE-----69043 B 1992IE-0001447 19920701;  
RO-----111569 B1 1992RO-0200738 19920528; HU-----211401 B 1992HU-0001609  
19920515; RU---2073666 C1 1992SU-5011728 19920520  
FDT AU---652826 B Previous Publ. AU---9217044; US---5434184 A Div ex  
US---5393779; DE--69204906 E Based on EP-----516349; ES---2076688 T3 Based  
on EP-----516349; US---5480910 A Div ex US---5393779, Cont of US---5434184;  
HU---211401 B Previous Publ. HU-----62256

PRAI 1991GB-0011426 19910528

AN 1992-400703 [49] WPIDS

AB EP 516349 A UPAB: 19941010

4-(2-(2-Hydroxy-2-phenylethylamino)ethoxy)-phenylacetic acid of formula  
(I), its bioprecursors and its salts are new.

USE - (I) is a beta 3-adrenoceptor agonist and produces a thermogenic  
effect. (I) is useful for treating obesity and related conditions such as  
mature onset diabetes associated with obesity. Dose is 0.002-20 (pref.  
0.5-5)mg/kg/day. Also (i) improves glucose tolerance and have  
hypoglycaemic activity and can be used to treat non-insulin dependent  
diabetes mellitus (NIDDM), and conditions where insulin resistance is  
important, e.g., hypertension, hyperlipidaemia and decreased fibrinolysis  
(Reaven's syndrome or Syndrome X); (ii) lowers triglyceride and  
cholesterol levels and raises high density lipoprotein (HDL) levels and  
can be used to treat hypertriglyceridaemia, hypercholesterolaemia and  
conditions of low HDL levels, and atherosclerotic disease (opt. in  
combination with other antiatherosclerotic agents such as fibrates,  
HMG-CoA reductase inhibitors, cholesterol absorption inhibitors, acyl  
CoA:cholesterol acyltransferase inhibitors, anion exchange resins,  
nicotinic acid or its derivs., vitamin E or thyromimetics); and (iii)  
stimulates the 'atypical' beta-adrenoceptors in the gastrointestinal tract  
and so inhibit gastrointestinal motility and can be used to treat, e.g.,  
inflammatory bowel disease, (e.g., Crohns disease and ulcerative colitis),  
irritable bowel syndrome, non-specific diarrhoea and dumping syndrome.

Dwg.0/0

Dwg.0/0

ABEQ ZA 9203356 A UPAB: 19931116

4-(2-(2-Hydroxy-2-phenylethylamino)ethoxy)-phenylacetic acid of formula  
(I), its bioprecursors and its salts are new.

Use - (I) is a beta 3-adrenoceptor agonist and produces a thermogenic  
effect. (I) is useful for treating obesity and related conditions such as  
mature onset diabetes associated with obesity. Dose is 0.002-20 (pref.  
0.5-5) mg/kg/day. Also (i) improves glucose tolerance and have  
hypoglycaemic activity and can be used to treat non-insulin dependent  
diabetes mellitus (NIDDM), and conditions where insulin resistance is  
important, e.g., hypertension, hyperlipidaemia and decreased fibrinolysis  
(Reaven's syndrome or Syndrome X); (ii) lowers triglyceride and  
cholesterol levels and raises high density lipoprotein (HDL) levels and  
can be used to treat hypertriglyceridaemia, hypercholesterolaemia and  
conditions of low HDL levels, and atherosclerotic disease (opt. in  
combination with other antiatherosclerotic agents such as fibrates,  
HMG-CoA reductase inhibitors, cholesterol absorption inhibitors, acyl  
CoA:cholesterol acyltransferase inhibitors, anion exchange resins,  
nicotinic acid or its derivs., vitamin E or thyromimetics); and (iii)  
stimulates the 'atypical' beta-adrenoceptors in the gastrointestinal tract

BEST AVAILABLE COPY

and so inhibit gastrointestinal motivity and can be used to treat, e.g., inflammatory bowel disease (e.g. Crohns disease and ulcerative colitis), irritable bowel syndrome, non-specific diarrrhoea and dumping syndrome.

ABEQ US 5393779 A UPAB: 19950412

4-(2-(2-hydroxy- 2-phenylethylamino) ethoxy)phenylacetic acid of formula (I), bioprecursors esp. esters and amides., and salts are new.

Cpds. of formula (II), R3 = 1-6C alkoxy are pref.

Specifically claimed cpds. include (R)-4-(2-(2-hydroxy-2-phenylethylamino)ethoxy)-phenyl acetic acid.

USE - (I) are beta2-adrenoreceptor agonists with thermogenic and hypoglycaemic action used to treat obesity, diabetes, hypertension, hyperlipidaemia and decreased fibrinolysis.

Dwg.0/0

ABEQ US 5434184 A UPAB: 19950904

Treatment of diseases mediated through 3-adrenoceptors comprises admin. of a 4-(2-(2-hydroxy-2-phenylethylamino)phenylalactic acid of formula (I), bioprecursors or salts. (I) stimulates thermogenesis and improves glucose tolerance.

USE - Used in the treatment of obesity, mature onset diabetes, NIDDM, hypertension and/or hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, atherosclerosis and low HDL levels. Dosage is e.g. 0.002-20 (0.5-5) mg/kg/day.

Dwg.0/0

ABEQ EP 516349 B UPAB: 19951026

A compound of the formula (I), or a bioprecursor or a pharmaceutically acceptable salt thereof.

Dwg.0/0

ABEQ US 5480910 A UPAB: 19960222

A method of inhibiting gastrointestinal motility by administering a pharmaceutically effective amount of a compound of the formula  $C_6H_5-CH(OH)CH_2NHCH_2CH_2O-p-C_6H_4-CH_2COOH$  (I) or a bio-precursor or a pharmaceutically acceptable salt thereof to a patient in need thereof.

Dwg.0/0